Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | GLS | O94925 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8722201 | 0.86 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1RAB9AKMT2AMAPK1 | |
| SCHEMBL19476144 | 0.82 | MMP13 (0.60) | SMN1; SMN2ALDH1A1RAB9AKMT2AMAPK1 | |
| SCHEMBL29505784 | 0.78 | SLC40A1 (0.48) | — | |
| Hydrochloric Acid SCHEMBL29505674 | 0.77 | SLC40A1 (0.49) | — | |
| SCHEMBL29505822 | 0.77 | SLC40A1 (0.48) | SMN1; SMN2KMT2AMAPK1HPGDPOLB | |
| SCHEMBL3800901 | 0.77 | MAPK10 (0.47) | ALDH1A1RAB9AMAPK1HPGDPOLB | |
| SCHEMBL166484 | 0.76 | LMNA (0.82) | SMN1; SMN2ALDH1A1RAB9AKMT2AHPGD | |
| SCHEMBL29367205 | 0.76 | HTT (0.69) | SMN1; SMN2ALDH1A1RAB9AKMT2AMAPK1 | |
| SCHEMBL2100277 | 0.76 | NPC1 (0.58) | SMN1; SMN2ALDH1A1RAB9AKMT2ANPC1 | |
| SCHEMBL18415475 | 0.76 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1RAB9AKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114668761-A | Novel ferroportin inhibitors | 威佛（国际）股份公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-108290878-B | Novel ferroportin inhibitors | 威佛（国际）股份公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRM1, GRIN1, GRM2 | SMN1; SMN2 1854/4885ALDH1A1 2269/4885RAB9A 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.